Study to assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD3043
Study identifier:D0510C00002
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
Phase I, Single Centre, Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous AZD3043 after a Single Ascending Bolus Dose, and a Single Ascending Bolus Dose Followed by a Single Infusion Dose in Healthy Volunteers
Medical condition
Healthy
Phase
Phase 1
Healthy volunteers
Yes
Study drug
AZD3043
Sex
All
Actual Enrollment
72
Study type
Interventional
Age
18 Years - 65 Years
Date
Study Start Date: 01 Sept 2009
Primary Completion Date: -
Study Completion Date: 01 Dec 2009
Study design
Allocation: Non-randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 Intravenous solution given as a single ascending bolus dose | Drug: AZD3043 Intravenous solution given as bolus dose (part A) and as bolus dose followed by infusion (part B) |
| Experimental: 2 Intravenous solution given as a single ascending bolus dose followed by a single infusion | Drug: AZD3043 Intravenous solution given as bolus dose (part A) and as bolus dose followed by infusion (part B) |
Contacts
Investigators
Principal Investigator
Johan Wemer
AstraZeneca
